Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients - Wikidata - wikimedia - TriplyDB

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

http://www.wikidata.org/entity/Q33426958

about

Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma Sunitinib in the treatment of metastatic renal cell carcinoma Renal cell carcinoma.Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics.Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.Sunitinib in kidney cancer: 10 years of experience and development.Sunitinib side effects as surrogate biomarkers of efficacy.Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib.Clinical guidance for radioiodine refractory differentiated thyroid cancer.Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma.The effect of information on preferences for treatments of metastatic renal cell carcinoma.On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.Hypertension in malignancy-an underappreciated problem.Successful selective arterial embolizations for bone metastases in renal cell carcinoma integrated with systemic therapies: A case report.Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma

P2860

Q28067482-2E4F3770-7CEC-4A86-960E-AF5F8AA3D6E3 Q28072057-5782792B-C85B-4D71-8588-56AA211CF8F1 Q30235364-FDF41A21-6AB9-49E7-8158-D10B4ADF5500 Q37474651-5717EC47-1BEA-41BD-8C92-20CAEF57D82A Q37723370-90C26676-4543-41DF-9872-4571103973C8 Q38799848-84A3BE8D-FF73-4467-B1BC-0F8BD0D08CC8 Q38823987-BEB87C55-1387-472E-9CEA-ECE211E30F6E Q39038214-37B83974-0E36-452F-B4EF-556ABE7396F6 Q39092937-2419086C-05CA-4B48-982C-BB69A8A1CC4C Q41573990-6BF3EBC7-F76E-412D-98D9-7A5C9D3EF36B Q41897121-D8C35CD5-5A6E-419B-B611-1DFFBEB1AF1D Q47251997-80215677-3D62-4AA8-AFB6-E2723793ECA9 Q47863818-9B578315-17FC-4011-B247-F6B7E70556A8 Q48099902-B2A89B3A-F2FA-4A2D-AC6C-F67597399083 Q49635743-A20C04DA-47E6-4C27-9C9F-100FE86A75CC Q49997360-ECDBC5A7-625F-4F8C-8E32-47F468A0C41D Q50762112-93BECD69-806E-4C76-8620-60D560F8C5EB Q53136887-AA8908CA-D816-48A8-A3D6-F16902ACCB44 Q53718852-2415E3E8-4C23-4323-8C53-AF3DE4047C0E Q55066009-67509AFD-7068-4040-BFEB-22A7328AB71F Q55071881-25845458-87A6-4FB7-B42F-C239B12A84C1 Q55314333-0E222FB0-C0C2-49D9-ACAA-E947A98E1C0E Q57116754-DC4D31F4-0F21-485A-BD13-597BC928CDC6

P2860

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

http://www.wikidata.org/entity/Q33426958

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Sunitinib-associated hypertens ...... renal cell carcinoma patients

@ast

Sunitinib-associated hypertens ...... renal cell carcinoma patients

@en

type

label

Sunitinib-associated hypertens ...... renal cell carcinoma patients

@ast

Sunitinib-associated hypertens ...... renal cell carcinoma patients

@en

prefLabel

Sunitinib-associated hypertens ...... renal cell carcinoma patients

@ast

Sunitinib-associated hypertens ...... renal cell carcinoma patients

@en

P1433

Q33426958-016C687F-A812-4BF0-8751-566BD9FC973E

P1476

Q33426958-FE82340E-8355-425D-976E-5DAE292786E0

P2093

Q33426958-0D409C78-FEBC-4449-825D-38B172AC50C5

Q33426958-0F075B09-7269-44E4-823B-E1C917F2413D

Q33426958-1692B3AC-E170-45EA-B8F7-93D0F3A58348

Q33426958-3576F3A8-1EF1-4EAB-BCE6-2BC7790DB4C6

Q33426958-66F17B5D-EF1F-4F09-AF67-2E526C79B865

Q33426958-6BB22691-E2EE-4307-989B-43D56373A919

Q33426958-DB1D40BC-EEE1-4978-87BB-895D4EAAD079

P2860

Q33426958-1D17343C-32FD-4068-A54D-639128E24CAC

Q33426958-1FCEDF58-A4EE-4014-8585-3A18199DA98B

Q33426958-25A52A17-FBA8-4D93-BD79-5AF46323C247

Q33426958-2B91B262-F89D-400B-9E03-9B65F5095CA0

Q33426958-2BD7F1ED-D232-45F5-B4EB-B33A9F6F20AC

Q33426958-306F213A-B88B-4545-8EF2-79AC6AE72C95

Q33426958-307F2B12-DA4B-44A9-98DC-A79A7C2B7478

Q33426958-408DC8D6-528A-4F97-B6B1-B9F47A2BA67F

Q33426958-5CADAEE8-6B00-4121-B071-9515DA76CBBF

Q33426958-5D21D670-0BB6-48C5-9B28-E7D7A0914146

P2888

Q33426958-AB907A76-5D30-4154-B252-BFF82891DEDA

P304

Q33426958-6157084B-61BA-4985-BA7E-CCB282B905BB

P31

Q33426958-624E1838-9451-4288-8135-80094121136E

P356

Q33426958-89B8E641-26B8-4CC5-8AB6-949A0B2E84D6

P407

Q33426958-4B0AD9CD-15EB-477F-BB4B-DCD1ABBA2B9D

P433

Q33426958-CC2761D2-F450-41B3-AAA6-730853FB5779

P478

Q33426958-B70B9FB4-8384-42A7-8C9E-D19A109E2CE3

P50

Q33426958-14FDD346-1752-424E-AE3D-C9C2CFE00A8E

Q33426958-71329905-E6B4-4769-9ECA-9A96A0A49AF2

Q33426958-CDE427A1-9DFF-4670-B7A7-F839D1122B63

Q33426958-EA8F8CEE-6462-4CCE-986B-E90121E1CCAB

P577

Q33426958-13028791-867A-4057-9DA9-3279F6E82C54

P5875

Q33426958-FD8C7307-81FC-4FCC-9C3F-E098EBE91C38

P6179

Q33426958-86CD4D4E-303A-4DCB-8AD1-461433FF4DFA

P698

Q33426958-219EA190-8673-4E3E-ACCE-401819CB73C6

P921

Q33426958-5D99FD81-C5E8-4F0B-B806-30EA44A57AD2

P932

Q33426958-279E533F-4E5F-4685-A938-964CF17B560D

P356

P1433

British Journal of Cancer

P1476

Sunitinib-associated hypertens ...... renal cell carcinoma patients

@en

P2093

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Darrel P Cohen

http://www.w3.org/2001/XMLSchema#string

David Goldstein

http://www.w3.org/2001/XMLSchema#string

Georg A Bjarnason

http://www.w3.org/2001/XMLSchema#string

Mellar P Davis

http://www.w3.org/2001/XMLSchema#string

Robin Wiltshire

http://www.w3.org/2001/XMLSchema#string

Xun Lin

http://www.w3.org/2001/XMLSchema#string

P2860

How to calculate the dose of chemotherapy

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Sunitinib in patients with metastatic renal cell carcinoma.

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

Biomarkers of response and resistance to antiangiogenic therapy.

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

P2888

P304

1571-1580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2015.368

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

M. Dror Michaelson

P577

2015-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283208899

http://www.w3.org/2001/XMLSchema#string

P6179

1036025400

http://www.w3.org/2001/XMLSchema#string

P698

26492223

http://www.w3.org/2001/XMLSchema#string

P921

P932

4705883

http://www.w3.org/2001/XMLSchema#string